Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients

Mostrar otras versiones (1)

The development of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following infection or vaccination is likely to be critical for the development of sufficient population immunity to drive cessation of the coronavirus disease of 2019 (COVID-19) pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Luchsinger, Larry L., Ransegnola, Brett P., Jin, Daniel K., Muecksch, Frauke, Weisblum, Yiska, Bao, Weili, George, Parakkal Jovvian, Rodriguez, Marilis, Tricoche, Nancy, Schmidt, Fabian, Gao, Chengjie, Jawahar, Shabnam, Pal, Mouli, Schnall, Emily, Zhang, Huan, Strauss, Donna, Yazdanbakhsh, Karina, Hillyer, Christopher D., Bieniasz, Paul D., Hatziioannou, Theodora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Immunoassays
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685895/
https://www.ncbi.nlm.nih.gov/pubmed/32917729
http://dx.doi.org/10.1128/JCM.02005-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685895/
https://www.ncbi.nlm.nih.gov/pubmed/32917729
http://dx.doi.org/10.1128/JCM.02005-20

Ejemplares similares